Sun Pharma gains on EMA nod for Nidlegy

Sun Pharmaceuticals advanced 2.31% to Rs 1,568 after the European Medicines Agency (EMA) validated the submission of the marketing authorization application (MAA) for Nidlegy, which was finalized on 3 June 2024.